Alice O Kamphorst

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6812431/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial. The Lancet Gastroenterology and Hepatology, 2022, 7, 219-229.	8.1	79
2	Preclinical studies of the anti-tumor effects of novel Avian paramyxovirus 4 (APMV-4) oncolytic viral therapy combined with vascular endothelial growth factor-C (VEGF-C) in melanoma Journal of Clinical Oncology, 2022, 40, e15050-e15050.	1.6	0
3	Single-cell analysis of human non-small cell lung cancer lesions refines tumor classification and patient stratification. Cancer Cell, 2021, 39, 1594-1609.e12.	16.8	151
4	Immunology of COVID-19: Current State of the Science. Immunity, 2020, 52, 910-941.	14.3	1,387
5	CXCR3-CXCL9: It's All in the Tumor. Immunity, 2019, 50, 1347-1349.	14.3	69
6	β-Catenin Activation Promotes Immune Escape and Resistance to Anti–PD-1 Therapy in Hepatocellular Carcinoma. Cancer Discovery, 2019, 9, 1124-1141.	9.4	498
7	An intra-tumoral niche maintains and differentiates stem-like CD8 T cells. Nature, 2019, 576, 465-470.	27.8	510
8	Dynamic changes in the immune infiltrate within hepatocellular carcinoma tumor correlate with response to PD-1 blockade Journal of Clinical Oncology, 2019, 37, e15644-e15644.	1.6	0
9	CD8 T Cell Exhaustion in Chronic Infection and Cancer: Opportunities for Interventions. Annual Review of Medicine, 2018, 69, 301-318.	12.2	432
10	Comparison of the toxicity profile of PDâ€1 versus PDâ€L1 inhibitors in non–small cell lung cancer: A systematic analysis of the literature. Cancer, 2018, 124, 271-277.	4.1	265
11	Immune checkpoint inhibitors in advanced non–small cell lung cancer. Cancer, 2018, 124, 248-261.	4.1	94
12	Enhancing Fcl̂ ³ R-mediated antibody effector function during persistent viral infection. Science Immunology, 2018, 3, .	11.9	5
13	T cell receptor sequencing of activated CD8 T cells in the blood identifies tumor-infiltrating clones that expand after PD-1 therapy and radiation in a melanoma patient. Cancer Immunology, Immunotherapy, 2018, 67, 1767-1776.	4.2	51
14	Rescue of exhausted CD8 T cells by PD-1–targeted therapies is CD28-dependent. Science, 2017, 355, 1423-1427.	12.6	753
15	Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1–targeted therapy in lung cancer patients. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 4993-4998.	7.1	614
16	Cardiac allograft rejection as a complication of PD-1 checkpoint blockade for cancer immunotherapy: a case report. Cancer Immunology, Immunotherapy, 2017, 66, 45-50.	4.2	55
17	Dendritic Cells in Tolerance and Immunity against Pathogens. Journal of Immunology Research, 2016, 2016, 1-2.	2.2	1
18	Beyond adjuvants: Immunomodulation strategies to enhance T cell immunity. Vaccine, 2015, 33, B21-B28.	3.8	28

ALICE O KAMPHORST

#	Article	IF	CITATIONS
19	Antibody Effector Functions Mediated by FcÎ ³ -Receptors Are Compromised during Persistent Viral Infection. Immunity, 2015, 42, 367-378.	14.3	59
20	Abstract 1317: Biomarker evaluation for PD-1 targeted therapies in non-small cell lung cancer (NSCLC) patients. Cancer Research, 2015, 75, 1317-1317.	0.9	1
21	Interplay between regulatory T cells and PD-1 in modulating T cell exhaustion and viral control during chronic LCMV infection. Journal of Experimental Medicine, 2014, 211, 1905-1918.	8.5	182
22	Inflammatory Flt3I is essential to mobilize dendritic cells and for T cell responses during Plasmodium infection. Nature Medicine, 2013, 19, 730-738.	30.7	134
23	Manipulating the PD-1 pathway to improve immunity. Current Opinion in Immunology, 2013, 25, 381-388.	5.5	95
24	CD4 T-cell immunotherapy for chronic viral infections and cancer. Immunotherapy, 2013, 5, 975-987.	2.0	52
25	Zinc finger transcription factor zDC is a negative regulator required to prevent activation of classical dendritic cells in the steady state. Journal of Experimental Medicine, 2012, 209, 1583-1593.	8.5	98
26	Expression of the zinc finger transcription factor zDC (Zbtb46, Btbd4) defines the classical dendritic cell lineage. Journal of Experimental Medicine, 2012, 209, 1153-1165.	8.5	429
27	Antigen-specific CD4 T-cell help rescues exhausted CD8 T cells during chronic viral infection. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 21182-21187.	7.1	155
28	A dynamic T cell–limited checkpoint regulates affinity-dependent B cell entry into the germinal center. Journal of Experimental Medicine, 2011, 208, 1243-1252.	8.5	349
29	Innate profiles of cytokines implicated on oral tolerance correlate with low―or highâ€suppression of humoral response. Immunology, 2010, 130, 447-457.	4.4	7
30	Route of Antigen Uptake Differentially Impacts Presentation by Dendritic Cells and Activated Monocytes. Journal of Immunology, 2010, 185, 3426-3435.	0.8	198
31	Germinal Center Dynamics Revealed by Multiphoton Microscopy withÂa Photoactivatable Fluorescent Reporter. Cell, 2010, 143, 592-605.	28.9	1,026
32	A Role for Lipid Bodies in the Cross-presentation of Phagocytosed Antigens by MHC Class I in Dendritic Cells. Immunity, 2009, 31, 232-244.	14.3	146
33	Sustained antigen presentation can promote an immunogenic T cell response, like dendritic cell activation. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 15460-15465.	7.1	65
34	A Mammalian microRNA Expression Atlas Based on Small RNA Library Sequencing. Cell, 2007, 129, 1401-1414.	28.9	3,390
35	Differential Antigen Processing by Dendritic Cell Subsets in Vivo. Science, 2007, 315, 107-111.	12.6	1,214
36	The Nucleoporin Nup96 Is Required for Proper Expression of Interferon-Regulated Proteins and Functions. Immunity, 2006, 24, 295-304.	14.3	100

#	Article	IF	CITATIONS
37	Antigen targeting to dendritic cells elicits long-lived T cell help for antibody responses. Journal of Experimental Medicine, 2006, 203, 599-606.	8.5	232
38	Genetic Selection for Resistance or Susceptibility to Oral Tolerance to Ovalbumin Affects General Mechanisms of Tolerance Induction in Mice. Annals of the New York Academy of Sciences, 2004, 1029, 350-354.	3.8	6